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ABSTRACT
The electrooxidative behavior of pravastatin (PRV) in aqueous media was studied by square-wave voltammetry at a glassycarbon electrode (GCE) and at a screen-printed carbon electrode (SPCE). Maximum peak current intensities in a pH 5.0 buffer were
obtained at +1.3 V vs. AgCl/Ag and +1.0 V vs. Ag for the GCE and SPCE surface respectively. Validation of the developed methodologies revealed good performance characteristics and confirmed their applicability to the quantification of PRV in pharmaceutical
products, without significant sample pretreatment. A comparative analysis between the two electrode types showed that SPCEs are
preferred as an electrode surface because of their higher sensitivity and the elimination of the need to clean the electrode’s surface
for its renewal, which frequently is, if not always, the rate-limiting step in voltammetric analysis.
Key words: pravastatin, square-wave voltammetry, electrochemical oxidation, glassy-carbon electrode, screen-printed carbon
electrode

INTRODUCTION
Lipid-modifying interventions have been shown to
decrease the risk of coronary heart disease both in patients
with hypercholesterolaemia and in those with relatively
normal levels of low-density lipoprotein cholesterol(1).
Pravastatin (Figure 1) belongs to the class of the
most widely used lipid-lowering drugs, statins. It is a
water-soluble cholesterol-reducing agent, which acts
by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A
(HMG-CoA) reductase. The enzyme catalyses the conversion of HMG-CoA to mevalonate, the rate-limiting step
in cholesterol synthesis(2). Competitive inhibition of this
enzyme by the statins decreases hepatocyte cholesterol
synthesis(1).
A large number of high-performance liquid chromatographic (HPLC) procedures have been developed
for PRV determination in a variety of matrices, such as
pharmaceuticals, serum, plasma, urine and sewage. The
most recently used methods are based on HPLC coupled
with ultraviolet/diode array(3-7) and mass(5,8-15) detectors.
Recently, a visible spectrophotometric method has also
been described(16).
* Author for correspondence. Tel: +351-228340500 ext. 1915; Fax:
+351-228321159; E-mail: han@isep.ipp.pt

Prior to the present work, there was only one electroanalytical study on PRV that had been published(17). The
study focused on the reductive and adsorptive behaviours
of PRV at a hanging mercury-drop electrode. No study on
the oxidative behaviour of PRV has been published to date.
Within the field of electroanalytical science, various
kinds of disposable electrochemical sensors based on
SPCEs are becoming increasingly important, as they help
in the development of on-site monitoring for clinical,
environmental, biological, food and industrial analysis.

HO
CO–2
OH

O
O

H3C

H

CH3

H3C

HO

Figure 1. Chemical structure of pravastatin.
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Features such as design flexibility, good reproducibility,
low reagent consumption and particularly the possibility
of mass production, make them an attractive alternative
for sensor building materials(18).
In the present work, the oxidation of PRV at a
glassy-carbon electrode (GCE) and at a screen-printed
carbon electrode (SPCE) was studied with the use of
square-wave voltammetry (SWV). Two different methods
were developed and successfully applied to the quantification of PRV in a pharmaceutical product of current
therapeutic use.

MATERIALS AND METHODS
Pravastatin sodium standard was purchased
from Sigma-Aldrich and used without further purification. The standard was stored at 4°C. Stock solutions were obtained by dissolving adequately weighed
amounts of the standard in deionised water (conductivity
< 0.1 µS cm-1). To obtain the desired concentration for
analysis, the stock solutions were diluted with electrolyte solution [Britton-Robinson buffer (I = 0.3 mol/L), pH
5.0]. All other chemicals were of analytical grade.
Voltammetric measurements were performed with an
Autolab PGSTAT12 potentiostat (Metrohm-EcoChemie,
Utrecht, The Netherlands), controlled by a computer
installed with GPES 4.9 software (Metrohm-EcoChemie
Utrecht, The Netherlands). When using the GCE, the
potentiostat was coupled with a Metrohm 663 VA stand
containing a three-electrode cell (Metrohm). The cell
consisted of a glassy-carbon working electrode (d = 2 mm),
an Ag/AgCl/KCl (3 mol/L) reference electrode and a glassycarbon auxiliary electrode. Commercially available SPCEs
(ref. 110 - DropSens, Oviedo, Spain) were also used. These
electrodes consisted of a carbon working disk electrode
(d = 4 mm), an auxiliary carbon electrode and a silver
pseudo-reference electrode, all printed on the same alumina
strip. An insulating area served to delimit the working
area and electrical contacts. With these electrodes, the
experimental set-up was similar to that mentioned above,
replacing the electrode-cell with an adaptor for the SPCEs
(DSC - DropSens, Oviedo, Spain).
Between measurements, SPCEs were replaced while
the surface of the GCE had to be cleaned. The cleaning
procedure involved polishing the electrode surface on an
abrasive cloth with Al2O3 (0.3 mm, BDH chemicals). The
electrodes were then rinsed with deionised water and dried.
For assays using the GCE, the background voltammogram was obtained by introducing 10.00 mL or
15.00 mL of supporting electrolyte into a voltammetric
cell. Before analysis, deoxygenation was performed by
purging the electrolyte with oxygen-free nitrogen for
300 s, with stirring. After the deoxygenation process,
the stirring was stopped and the background voltammogram was recorded. The electrode was then cleaned
and the required amount of PRV standard solution was

added to the cell. The procedure was repeated using a
10-s nitrogen-purge between measurements. For SPCEs,
voltammetric measurements were performed by placing a
50-µL drop of the analyte solution over the exposed area.
To record the background signal, the analyte solution was
replaced with the electrolyte. In both cases, the squarewave voltammograms were obtained by applying a
potential scan in the positive direction.
To evaluate the precision of using the GCE for the
analysis of PRV in terms of repeatability and intermediate precision, PRV solutions of 8.0 × 10 -5, 1.0 × 10 -4
and 1.2 × 10 -4 mol/L were analysed five times per day
over three consecutive days. For the SPCE, the same
approach was used by analysing PRV solutions of 1.0 ×
10 -4, 3.0 × 10 -4 and 7.5 × 10 -4 mol/L.
In order to evaluate the selectivity and accuracy of
the procedure for the analysis of PRV in Pravastatin Alter
(Alter S.A., 10 mg PRV/tablet, gross weight = 0.1 g), five
tablets were weighed and finely powdered. About 0.108 g
of the resulting mixture was transferred to a 10.00-mL
volumetric flask and water was added. The flask was
then placed in an ultrasonic bath for 15 min to extract
PRV from the matrix. For the method using the GCE, a
442.5-µL aliquot of the resulting suspension was placed
in 10.00 mL of supporting electrolyte contained in the
voltammetric cell and analysed. Subsequently, three
standard additions were made (5.0 × 10 -5, 1.00 × 10 -4 and
1.50 × 10 -4 mol/L) and the voltammetric scan was applied
after each addition. Selectivity was evaluated by recovery
studies and comparing the slope of an external standard
calibration curve with the slope of the standard addition
curve. For the method using the SPCE, five 105.9-µL
aliquots of the suspension were placed in five 5.00-mL
volumetric flasks and standard additions of 0, 5.00 ×
10 -5, 2.50 × 10 -4, 4.50 × 10 -4 and 7.00 × 10 -4 mol/L were
made. The resulting solutions were then analysed by the
developed SWV procedure. Selectivity was evaluated by
comparing the slope of an external standard calibration
curve with the slope of the standard addition curve.
For the quantification of PRV in Pravastatin Alter,
five tablets were weighed and finely powdered. About
0.108 g of the resulting mixture was transferred to
50.00-mL (GCE) or 10.00-mL (SPCE) volumetric flasks
and placed in an ultrasonic bath for 15 min in order to
extract PRV from the matrix. The resulting suspension
was then diluted in the voltammetric cell (GCE) or in
5.00-mL volumetric flasks (SPCE) with supporting electrolyte to obtain the desired PRV concentrations (within
the linear ranges) for analysis. Quantification of PRV was
carried out by the external calibration method.

RESULTS AND DISCUSSION
I. Optimization
The optimization of the experimental conditions was
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performed using the glassy-carbon electrode.
High-frequency square-wave voltammetry was used
to study the electrochemical oxidation of PRV at the
glassy-carbon electrode. The electrochemical behavior
of PRV (1.0 × 10 -4 mol/L) was verified over the pH
range 1.40 - 11.70, using Britton-Robinson buffers as
supporting electrolytes. The results showed that PRV
gave rise to one anodic peak over the whole pH range
investigated. At a pH value of 5.0, the highest and bestdefined oxidation peak was obtained at approximately
+1.3 V vs. AgCl/Ag.
Since SWV was used for the determination of PRV
in a pharmaceutical dosage form, it was necessary to
determine the most adequate SWV parameters in order to
obtain the best peak characteristics for PRV analysis. The
frequency ( f ), pulse step (∆Es) and pulse amplitude (∆Ep)
were optimized using a 1.0 × 10 -4 mol/L PRV solution in
a Britton-Robinson buffer (pH = 5.0). The influence of f
was studied over a range of 10-100 Hz. The peak current
intensity (ip) increased linearly until 90 Hz (ip = 0.016 ×
f + 0.86; ip - µA, f - Hz). A less significant increase of ip
was observed after this value. Hence, an f of 90 Hz was
adopted in subsequent experiments. Variation of DEs
from 1 to 10 mV and of ∆Ep from 5 to 50 mV resulted
in a marked increased of ip up to 5.25 mV (ip = 0.53 ×
∆Es + 1.3; ip - µA, ∆Es - mV) and 40 mV (ip = 0.12 × ∆Ep

+ 0.52; ip - µA, ∆Ep - mV) respectively, after which the
ip values remained constant. These optimized conditions
were used in all the subsequent studies.
II. Validation
(I) Glassy-Carbon Electrode
A linear relationship between peak current intensity and PRV concentration was obtained for the interval
between 6.0 × 10 -5 and 9.2 × 10 -4 mol/L. Typical voltammograms of PRV concentrations within this range are
shown in Figure 2.
Limits of detection (LOD) and quantification (LOQ)
(19)
as well as other calibration plot characteristics are
given in Table 1. The results of the precision studies
(Table 2) confirmed that the method was precise.
To verify whether excipients in the Pravastatin Alter
tablets interfered with the analysis, recovery and selectivity studies were performed. Recovery values between
97.9% and 102.3% were obtained, confirming that the
method was accurate and that excipients did not interfere significantly with the analysis. In addition, the ratio
between the slope of the external standard calibration

Table 1. Analytical data from the calibration plot in the determination of PRV by SWV
60

Property

55

GCE

SPCE

Linear range (µmol/L)

60 - 920

50 - 1000

Correlation coefficient

0.999 (n = 8)

0.999 (n = 6)

5.43

82

Standard error slope (mA L mol )

0.04

1.3

Intercept (µA)

0.20

8.7

Standard error intercept (µA)

0.02

0.8

LOD (µmol/L)

11

30

LOQ (µmol/L)

37

101

-1

Slope (mA L mol )

50

-1

i / µA

45

40

35

30

Table 2. Results from the evaluation of precision*

25

Electrode

20

GCE
15
0.7

0.9

1.1

1.3

1.5

1.7

E/V

Figure 2. Square-wave voltammograms of PRV in the linear range by
GCE. [PRV] (× 10 -4 mol/L): 1.00, 1.50, 2.00, 2.50 and 3.00 ( f : 90 Hz;
DEs: 5.25 mV; DEp: 40 mV). (i/μA: current intensity/micro-ampere;
E/V: applied potential/volt).

SPCE

Repeatability**
(RSD %, n = 5)

Intermediate Precision**
(RSD %, n = 3)

1.4 (0.8)

1.0 (0.8)

0.9 (1.0)

3.8 (1.0)

5.3 (1.2)

3.0 (1.2)

4.2 (1.0)

3.5 (1.0)

4.4 (3.0)

6.1 (3.0)

1.3 (7.5)

0.6 (7.5)

-4

* Concentrations in 10 mol/L are given in parentheses.
** RSD: Relative standard deviation
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plot and the slope of a standard addition curve was found
to be 1.1, indicating that the method was selective for the
determination of PRV in this sample.

150

(II) Screen-Printed Carbon Electrodes

125

III. Application

100

i / µA

With the previously optimized SWV parameters
using the glassy-carbon electrode, the oxidation peak
of PRV was obtained at about +1.0 V vs. Ag. Using the
previously optimized SWV parameters and analytical
conditions, validation of the SWV procedure for PRV
analysis was repeated using SPCEs. Table 1 lists the
characteristics of the calibration curve and the respective
LOD and LOQ values calculated using the curve. Typical
voltammograms of PRV concentrations within the linear
range are shown in Figure 3.
The results from the evaluation of precision are
reported in Table 2, indicating that the method was
precise. A 1.1 ratio between the slope of an external standard calibration plot and the slope of a standard addition
curve confirmed the method’s selectivity.

75

50

25

0

In the application of the SWV method to the quantification of PRV in the pharmaceutical product, Pravastatin
Alter, the labeled values (10 mg per tablet) were in good
agreement with the obtained results: 9.97 ± 1.3 mg/tablet
(n = 3) using the SPCE and 9.78 ± 0.84 mg/tablet (n = 3)
using the GCE.

CONCLUSIONS
The present study showed that both electrode types
can be successfully applied to the quantification of PRV
in a pharmaceutical product. No significant differences
were found in terms of detection limits, precision and
accuracy. Both methods provided simple, sensitive, accurate, selective, fast and low cost quantifications of PRV in
pharmaceutical dosage forms.
Besides the better sensitivity of the SPCE, which is
probably due to the difference in the active area of the
electrode, SPCEs have another important advantage over
the GCE - The use of SPCEs eliminated the need to clean
the electrode’s surface for its renewal, which frequently
is, if not always, the rate-limiting step in voltammetric
analysis.
When compared with published non-chromatographic methods for pravastatin analysis in pharmaceuticals, the obtained linear ranges and limits of detection
were in the same order of magnitude. Although the limits
of detection of the developed methods were 2 to 4 orders
of magnitude higher than those obtained with most of
the published chromatographic methods, they were sufficiently low for the proposed application.

0.6

0.9

1.2

1.5

E/V

Figure 3. Square-wave voltammograms of PRV in the linear range by
SPCE.
[PRV] (× 10 -4 mol/L): 0.500, 1.00, 3.00, 5.00, 7.00 and 10.0 ( f : 90
Hz; DE s: 5.25 mV; DE p: 40 mV). (i/μA: current intensity/microampere; E/V: applied potential/volt).
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